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IMPORTANCE Nonadherence to treatment with medicines is common globally, even for
life-saving treatments. Cost is one important barrier to access, and only some jurisdictions
providemedicines at no charge to patients.
OBJECTIVE To determine whether providing essential medicines at no charge to outpatients
who reported not being able to afford medicines improves adherence.
DESIGN, SETTING, AND PARTICIPANTS Amulticenter, unblinded, parallel, 2-group, superiority,
outcomes assessor–blinded, individually randomized clinical trial conducted at 9 primary care
sites in Ontario, Canada, enrolled 786 patients between June 1, 2016, and April 28, 2017, who
reported cost-related nonadherence. Follow-up occurred at 12 months. The primary analysis
was performed using an intention-to-treat principle.
INTERVENTIONS Patients were randomly allocated to receive free medicines on a list of
essential medicines in addition to otherwise usual care (n = 395) or usual medicine access
and usual care (n = 391).
MAIN OUTCOMES ANDMEASURES The primary outcomewas adherence to treatment
with all medicines that were appropriately prescribed for 1 year. Secondary outcomes were
hemoglobin A1c level, blood pressure, and low-density lipoprotein cholesterol levels 1 year
after randomization in participants taking correspondingmedicines.
RESULTS Among the 786 participants analyzed (439women and 347men; mean [SD] age,
51.7 [14.3] years), 764 completed the trial. Adherence to treatment with all medicines was
higher in those randomized to receive free distribution (151 of 395 [38.2%]) compared with
usual access (104 of 391 [26.6%]; difference, 11.6%; 95% CI, 4.9%-18.4%). Control of type 1
and 2 diabetes was not significantly improved by free distribution (hemoglobin A1c, −0.38%;
95% CI, −0.76% to 0.00%), systolic blood pressure was reduced (−7.2 mmHg; 95% CI,
−11.7 to −2.8mmHg), and low-density lipoprotein cholesterol levels were not affected
(−2.3 mg/dL; 95% CI, −14.7 to 10.0mg/dL).
CONCLUSIONS AND RELEVANCE The distribution of essential medicines at no charge for
1 year increased adherence to treatment with medicines and improved some, but not other,
disease-specific surrogate health outcomes. These findings could help inform changes to
medicine access policies such as publicly funding essential medicines.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02744963
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L ifesaving medicines such as treatments for cardiovas-cular disease and HIV and AIDS are often not acces-sible because of the cost to patients, among other
reasons.1 Global estimates of medication nonadherence are
between 40% and 60% for treatments for chronic diseases.2
A systematic review of interventions to improve adherence
identified few effective interventions and underscored the
need for additional high-quality studies.3 Providing certain
medicines at no charge for people with specific conditions
such as myocardial infarction, hypertension, HIV and AIDS,
and schizophrenia can improve surrogate and direct health
measures related to those conditions.4-7 The World Health
Organization recommends that countries develop a list of
essential medicines “that satisfy the priority health care
needs of the population” for the purpose of increasing access
and quality of care, and facilitating medicine access is one
way to help achieve universal health coverage.8
Previous studies such as the RAND Health Insurance
Experiment did not isolate the effect of medicine access
from that of health care access.9 Canada is a suitable setting
to measure the effects of medicine distribution because phy-
sician care and hospitalizations are universally publicly
funded, while medicines are not.10 Public coverage of medi-
cines used outside of Canadian hospitals varies by province,
but is most frequently offered for specific groups, such as
people receiving social assistance and those older than 65
years.10 Approximately 55% of people in Ontario, Canada,
have employer-based private insurance plans that typically
cover medicines with copayments or deductibles, while
approximately 28% have public insurance that also involve
copayments and deductibles.11
We conducted a randomized clinical trial examining the
effect of providing Canadian outpatients who reported not
being able to affordmedicineswith free distributionof essen-
tialmedicines. Because theprovidedmedicines includedonly
treatments that have beenwell established as effective—such
as those for cardiovascular disease, HIV and AIDS, and pneu-
monia—adherence was chosen as the primary outcome, and
surrogate health outcomes were the secondary outcomes.
Methods
Study Design
TheCarefullySelectedandEasilyAccessibleatNoChargeMedi-
cines (CLEANMeds) trial is a multicenter, unblinded, parallel,
2-group, superiority, outcomes assessor–blinded, individually
randomized clinical trialwith 1:1 allocation conducted at 9pri-
mary care sites in Ontario, Canada, that enrolled patients be-
tween June 1, 2016, and April 28, 2017. The trial protocol is
available in Supplement 1. The trial was registered with
ClinicalTrials.gov (NCT02744963) and a protocol has been
published.12 The trial is reported in accordance with the 2010
CONSORT statement13 and the intervention is described using
the TIDieR (Template for Intervention Description and
Replication) checklist.14 After registration with ClinicalTrials.
gov, publicationof theprotocol, and initiationof the study, the
duration of the trial was extended from 12 to 24monthswhen
additional fundingwasobtained(trialprotocol inSupplement1).
For theanalysis of theprimaryoutcome,weoriginallyplanned
to use electronic pill bottle cap devices in one-seventh of
participants toconfirmadherencemeasurements,butowing to
a large amount ofmissingdata inboth groupswe removed this
measure fromthedefinitionof theprimaryoutcome;wereport
the results when the available electronic pill bottle cap device
data were used in eTable 1 in Supplement 2. A data and safety
monitoringboardmet toensure thatmedication incidentswere
properly addressed and that the interventionwasnot harming
participants. Ethics approval for the conduct of this studywas
obtainedfromtheStMichael’sResearchEthicsBoard, theHuron
ShoresFamilyHealthTeamResearchEthicsCommittee,andthe
Laurentian University Research Ethics Board. All enrolled
participants providedwritten informed consent.
Patients
Patients 18 years or older who self-reported medication non-
adherenceowing to cost in the last 12monthswere eligible for
inclusion. After potentially eligible participants were identi-
fiedbycliniciansat routinevisits, studypersonnelaskedaques-
tion adapted from the Commonwealth Fund International
Health Policy Survey to confirm cost-related nonadherence:
“In the last twelve months, did you not fill a prescription or
do anything tomake a prescription last longer because of the
cost?”15(p30) We excluded family members living at the same
address as participants already enrolled in the study to avoid
contamination and excluded patients who joined the clinic
within the last6months todeterpatients fromjoining theprac-
tice to enroll in the study.
Trial Procedures
Patients who met the eligibility criteria were randomly allo-
cated to 1of2groups.The interventiongroup received freedis-
tribution of essential medicines. The control group accessed
medications as usual. Randomization and allocation conceal-
ment were achieved through a web-based tool that was ac-
cessed through the REDCap electronic case report forms
application and was stratified by center and blocked using
permuted blocks of 2 to 4.16
Key Points
Question Does providing a comprehensive set of essential
medicines at no charge to primary care patients who have
difficulty affordingmedicines improve treatment adherence?
Findings In this randomized clinical trial of 786 primary care
patients, free distribution of essential medicines vs usual access
resulted in greater adherence to treatment with medicines
(absolute risk difference, 11.6%). Control of type 1 and 2 diabetes
was not significantly improved by free distribution of essential
medicines (hemoglobin A1c, −0.38%), systolic blood pressure was
reduced (−7.2 mmHg), and low-density lipoprotein cholesterol
levels were not affected (−2.3 mg/dL).
Meaning Distributing essential medicines at no charge increased
adherence to appropriately prescribed treatment with medicines
and improved some disease-specific surrogate health outcomes.
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Patients in the intervention group received free distribu-
tion of medicines on a list of essential medicines as well
as otherwise usual care. The list of 128 essential medicines
was adapted from the 2013 World Health Organization
Model List of Essential Medicines based on Canadian clinical
practiceguidelines,17 suggestions fromcliniciansandpatients,
prescribing volumes, and evidence syntheses (eAppendix 1 in
Supplement2).18Themedicines included treatments for acute
conditions (eg, antibiotics and analgesics) and chronic condi-
tions(eg,antipsychotics,antiretrovirals,glucose-loweringmedi-
cines, and antihypertensives). Patients could be prescribed
medicines thatwere not on the essential list and could access
them in the usual way (eg, by paying for them). Participants
couldbe switched fromamedicinenoton the list to anequiva-
lent that was on the list. Medicine distribution was primarily
throughthemail toanaddressoftheparticipant’schoice.Acom-
munity pharmacist (N.U.; with a Bachelor of Science in Phar-
macyandmore than 15yearsof experience) contactedpatients
by telephone fromapharmacyestablished for the study.Medi-
cines that needed to be started in a timely fashion (eg, anti-
infectives,analgesics,diuretics,bronchodilators, antihyperten-
sives, andantipsychotics)werealsostoredateachstudysite for
dispensing by clinicians. Controlled substances (eg, opioids,
sedatives, and stimulants) were not included in the interven-
tion;patients accessed thesemedications in theusual fashion.
Participants allocated to the control grouphad their usual
access tomedicines.Typical annualout-of-pocket costs topar-
ticipants in the control group were the full cost of medicines
for those with no insurance (eg, approximately $800, as well
as dispensing fees of approximately $10 per prescription for a
patient taking oral diabetes medicines), a deductible for an
older adult with public drug coverage (eg, $100 plus copay-
mentsof$4 foreachprescription filled), or apercentageof total
medicine costs for those with private insurance (eg,
$160 = $800 × 20%,assuming80%coverage).Medicineswere
generallydispensedbycommunitypharmacies, someofwhich
offer local delivery services for medicines on request.
Outcomes
The follow-up period was 12 months. The prespecified pri-
mary outcomewas adherence to all appropriately prescribed
medicines.19 The primary outcome was determined at 12
months by assessing whether each prescription was both ap-
propriate (based on explicit criteria) and taken as prescribed
for at least 80% of expected doses.19 A participant was either
classifiedas receivingonlyappropriateprescriptionsandbeing
adherent to all of them (evidence of taking at least 80%of ex-
pected doses), or as having either received at least 1 poten-
tially inappropriate prescription or being nonadherent to at
least 1 medicine. We reviewed primary care prescribing rec-
ords to determine whether each prescription was potentially
inappropriateusing established criteria basedonlyon thepre-
scribedmedicines (eAppendix 2 in Supplement 2).20We con-
sidered as appropriate all prescriptions that did not meet
Figure. Participant FlowDiagram
1130 Patients assessed for eligibility
344 Excluded
109 Did not meet inclusion
criteria
235 Declined to participate
786 Randomized
395 Randomized to free medicine
distribution
395 Received intervention as
randomized
9 Withdrew consent
395 Analyzed
13 Withdrew consent
391 Analyzed
391 Randomized to usual medicine
access
391 Received intervention as
randomized
Table 1. Baseline Participant Characteristics by Group
Characteristic
Participants, No. (%)
Free Distribution
Group (n = 395)
Usual Access
Group (n = 391)
Female sex 220 (55.7) 219 (56.0)
Age, mean (SD), y 51.0 (14.2) 50.4 (14.3)
Age ≥65 y 71 (18.0) 64 (16.4)
Race/ethnicity
White 256 (64.8) 260 (66.5)
Black 35 (8.9) 39 (10.0)
Southeast or East Asian
(including Korean, Japanese,
Filipino, and Chinese)
28 (7.1) 19 (4.9)
South Asian 25 (6.3) 24 (6.1)
Latin American 10 (2.5) 15 (3.8)
Indigenous 12 (3.0) 14 (3.6)
West Asian (including Arab) 6 (1.5) 5 (1.3)
Mixed or other 22 (5.6) 8 (2.0)
Declined to provide 1 (0.3) 7 (1.8)
Main income source
Wages and salaries (including
self-employed)
218 (55.2) 221 (56.5)
Pension 50 (12.7) 42 (10.7)
Social support (eg, welfare
or disability)
36 (9.1) 47 (12.0)
Unemployment insurance 15 (3.8) 9 (2.3)
Other 56 (14.2) 51 (13.0)
Declined to provide 20 (5.1) 21 (5.4)
Household income, Can$a
<30 000 205 (51.9) 182 (46.5)
30 000-70 000 92 (23.3) 99 (25.3)
>70 000 21 (5.3) 22 (5.6)
Declined to provide 77 (19.5) 88 (22.5)
No. of medicines prescribed
at baseline, mean (SD)
5.3 (3.6) 5.6 (4.0)
Site
Urban 269 (68.1) 267 (68.3)
Rural 126 (31.9) 124 (31.7)
Prescribed
Diabetes treatment 89 (22.5) 91 (23.3)
Antihypertensive 122 (30.9) 114 (29.2)
Statin 81 (20.5) 81 (20.7)
a Themedian Canadian household income in 2015 was $70 336, and the poverty
line was $37 542.22
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criteria for being potentially inappropriate. Two adjudicators
independently applied the explicit criteria in a blinded fash-
ion; therewerenodisagreements. For adherence,weused the
lowest estimate from the 2methods used: reviews of primary
care records for prescription renewal intervals during the 12-
month studyperiod andpatient report of thenumber of doses
missed during the last week, as reported by telephone inter-
view or email survey between 9 and 12 months. Blinded ab-
straction ofmedical recordswas done by 1 adjudicator from a
teamof5andverifiedbyanotheraftera trainingperiod foreach
adjudicator.
The prespecified secondary outcomes were the propor-
tionofmedicines thatwere appropriately prescribed, thepro-
portion of medicines that met adherence criteria, hemoglo-
bin A1c levels in patients treated for type 1 or 2 diabetes
(adjusted for baseline), bloodpressure inpatients treatedwith
an antihypertensive (adjusted for baseline), and low-density
lipoprotein cholesterol levels in patients treatedwith a statin
(adjusted for baseline). Hemoglobin A1c, blood pressure, and
low-density lipoprotein cholesterol levelswereobtainedby re-
view of medical records during the baseline period (up to 3
monthsprior to randomization) andat follow-up (9-12months
after randomization).Cliniciansordered investigationsasusual
inbothgroups;no instructions related toclinical carewerepro-
vided by the trial team. To compare experiences between
groups, after a 9- to 12-month follow-up period we asked pa-
tients 14questions about their care,medicinedispensing, and
social circumstances (eTable 2 in Supplement 2). Serious
adverse events, including hospitalizations and deaths, were
ascertained through clinician reports, patient reports, and
reviews of the primary care medical records.
Statistical Analysis
The sample size was calculated to detect a 10% absolute dif-
ference (80% power, type I error of 5%) in the primary out-
comeofappropriateadherenceandassuming that40%to60%
ofpatients in the control groupwouldbe appropriately adher-
ent to allmedications.4,6,21 A sample size of 392per groupwas
required. Theprimary analysiswasperformedusing an inten-
tion-to-treat principle. Appropriate adherence was com-
pared using a χ2 test and the unadjusted treatment effect was
expressedas theabsolute riskdifference.For theprimaryanaly-
sis, P < .05was used to reject the null hypothesis of no differ-
ence. We did not correct for multiple comparisons because
comparisons other than for the prespecified primary and sec-
ondary outcomes are hypothesis generating. For the explor-
atory subgroup analysis, we fit a logistic regression model to
determinewhether the following characteristicsmodified the
effect of the intervention: age, sex, urban vs rural site, num-
ber of baseline medicines, and income.
Results
Patients
BetweenJune1,2016,andApril 28,2017, 1130 individuals iden-
tified as potentially eligible by clinicianswere assessed for eli-
gibility and 786 were randomly allocated (Figure). The char-
acteristics of participants in the 2 groups are summarized in
Table 1.22 For the 22 of 786 participants (2.8%)whowithdrew
consent—9 of 395 (2.3%) in the free distribution group and 13
of 391 (3.3%) in theusual access group—data collectedprior to
withdrawal were included in the analysis.
The categories of medicines prescribed were similar be-
tweengroups (Table 2). Commonlyprescribedmedicinesdur-
ing the study period included analgesics, diabetes treat-
ments, proton pump inhibitors, treatments for hypertension
or vascular disease, and treatments for asthma or chronic ob-
structive pulmonary disease.
Adherence
Free distribution increased the number of participants in the
freedistributiongroupwhowere appropriately adherent to all
medicines, comparedwith those in theusual access group (151
of 395 [38.2%] vs 104 of 391 [26.6%]; difference, 11.6%; 95%
CI, 4.9%-18.4%; P < .001) (Table 3). We performed sensitivity
analysesusing less stringentdefinitionsand found that thedif-
ference was similar in magnitude and remained statistically
significant (eTable 1 in Supplement 2). There was little indi-
cation of subgroup effects: no effectmodification termswere
statistically significantlydifferent (age, sex,urbanvs rural site,
number of baseline medicines, and income); the overall test
Table 2. Participants PrescribedMedicines by Anatomical Therapeutic Chemical Classification SystemMain Groups
Anatomical Therapeutic Chemical Main Group
(Examples of Medicines Commonly Prescribed)
Prescriptions, No. (%)
Free Distribution Group
(n = 2071)
Usual Access Group
(n = 2183)
Nervous system (gabapentin, sertraline, venlafaxine, and acetaminophen) 424 (20.5) 450 (20.6)
Alimentary tract and metabolism (metformin, pantoprazole, rabeprazole, and insulin) 381 (18.4) 403 (18.5)
Cardiovascular system (atorvastatin, ramipril, rosuvastatin, amlodipine, and hydrochlorothiazide) 326 (15.7) 366 (16.8)
Respiratory system (albuterol, fluticasone, and tiotropium) 274 (13.2) 264 (12.1)
Dermatologic (hydrocortisone and betamethasone) 161 (7.8) 159 (7.3)
Blood and blood-forming organs (acetylsalicylic acid and ferrous fumarate) 125 (6.0) 140 (6.4)
Musculoskeletal system (naproxen and ibuprofen) 117 (5.6) 128 (5.9)
Genitourinary system and sex hormones (estradiol) 116 (5.6) 124 (5.7)
Anti-infectives for systemic use (amoxicillin) 86 (4.2) 88 (4.0)
Systemic hormonal preparations (levothyroxine) 40 (1.9) 37 (1.7)
Other 21 (1.0) 24 (1.1)
Research Original Investigation Effect of Distributing Essential Medicines at No Charge on Treatment Adherence
E4 JAMA Internal Medicine Published online October 7, 2019 (Reprinted) jamainternalmedicine.com
Downloaded From: https://jamanetwork.com/ by a University of St. Andrews Library User  on 10/17/2019
of including effect modification was not statistically signifi-
cant; and the estimate of the effect of the intervention on ad-
herence was similar without adjustment for baseline charac-
teristics (odds ratio, 1.7; 95% CI, 1.3-2.3) andwith adjustment
(odds ratio, 1.7; 95% CI, 1.2-2.3).
Secondary Outcomes
The proportion of medicines each participant was adherent
to was higher in those receiving free distribution than those
with usual access (66.1% vs 56.4%; difference, 7.2%; 95% CI,
1.1%-14.0%; P = .02) and the proportion of potentially inap-
propriately prescribed medicines was lower in those with
free distribution than those with usual access (0.17% vs
0.85%; difference, −0.66%; 95% CI, −0.79% to −0.33%;
P = .007) (Table 3). Free distribution improved systolic
blood pressure among those prescribed an antihypertensive
drug compared with those receiving usual access (−7.2 mm
Hg; 95% CI, −11.7 to −2.8 mmHg; P = .002), but did not have
a statistically significant effect on the other surrogate health
outcomes such as low-density lipoprotein cholesterol level
(−2.3 mg/dL; 95% CI, −14.7 to 10.0 mg/dL; P = .70 [to con-
vert to millimoles per liter, multiply by 0.0259]), although
there was a nonsignificant decrease in hemoglobin A1c lev-
els in participants in the free distribution group who were
prescribed a diabetes treatment (−0.38%; 95% CI, −0.76% to
0.00%; P = .05 [to convert to proportion of total hemoglo-
bin, multiply by 0.01]) (Table 4).
There were statistically significant differences between
groups in 10 of the 14 patient-oriented outcomes (eTable 2 in
Supplement 2). Compared with the time of enrollment, par-
ticipants in the free distribution group weremore likely than
those in the usual care group to report receiving their medi-
cines before the previous prescription ran out (217 of 261
[83.1%]vs 157of 237 [66.2%];difference, 16.9%;95%CI, 9.0%-
24.8%), more likely to report that their care improved (123 of
266 [46.2%] vs 47 of 251 [18.7%]; difference, 27.5%; 95% CI,
19.4%-35.6%), and more likely to report being able to “make
ends meet” or afford necessities (230 of 266 [86.5%] vs 79 of
238 [33.2%]; difference 53.3%; 95% CI, 45.6%-60.9%). There
was no statistically significant difference between groups in
thefollowing5of 14patientorientedoutcomes: receivingmedi-
cines in good condition, receiving newmedicines quickly, re-
ported medicine adverse effects, having unanswered ques-
tions about medicines, information changing the way
medicineswere taken, and the information from thepharma-
cist and prescriber matching.
Safety
Therewasnosubstantialdifferencebetweenparticipants in the
free distribution group and those in the usual access group in
serious adverse events (33 of 395 [8.4%] vs 35 of 391 [9.0%];
P = .80).Hospitalizations (26of 395 [6.6%]vs 25of 391 [6.4%];
P > .99),deaths (8of395 [2.0%]vs8of391 [2.0%];P > .99), and
other serious adverse events (7 of 395 [1.8%]vs4of 391 [1.0%];
P = .55)werealsosimilarbetweenthefreedistributiongroupand
theusual access group.Therewere37medication incidents in-
volving32of395participants (8.1%) receiving freedistribution.
Discussion
In our multicenter randomized trial, distributing a compre-
hensive set of essential medicines at no charge improved
Table 3. Primary and Secondary Outcome Results by Group
Outcome
Free Distribution
Group (n = 395)
Usual Access
Group (n = 391)
Difference,
% (95% CI) P Value
Primary outcome, No. (%)
Participants appropriately
adherent to all medicines
151 (38.2) 104 (26.6) 11.6 (4.9 to 18.4) <.001
Secondary outcomes, %
Mean % of medicines adhered to
by each participanta
66.1 56.4 7.2 (1.1 to 14.0) .02
Mean % of medicines potentially
inappropriately prescribed to
each participanta
0.17 0.85 −0.66 (−0.79 to −0.33) .007
a Differences estimated from rate
ratios and estimatedmean
percentage in control group. Rate
ratio for medicines adhered to was
1.13 (95% CI, 1.02-1.25). Rate ratio
for potentially inappropriate
prescriptions was 0.22 (95% CI,
0.064-0.60).
Table 4. Secondary Surrogate Health Outcome Results by Group
Outcome
Free Distribution
Group
Usual Access
Group
Hemoglobin A1c, %
No. 73 68
Baseline, mean (SD) 8.20 (1.86) 8.15 (1.85)
Follow-up, mean (SD) 7.69 (1.50) 8.04 (1.58)
Difference (95% CI) −0.38 (−0.76 to 0.00) NA
P value .05 NA
Systolic blood pressure, mm Hg
No. 105 88
Baseline, mean (SD) 137 (19) 135 (17)
Follow-up, mean (SD) 132 (16) 139 (19)
Difference (95% CI) −7.2 (−11.7 to −2.8) NA
P value .002 NA
Diastolic blood pressure, mm Hg
No. 105 88
Baseline, mean (SD) 81 (13) 81 (11)
Follow-up, mean (SD) 78 (12) 80 (13)
Difference (95% CI) −2.0 (−5.0 to 1.0) NA
P value .19 NA
LDL cholesterol level, mg/dL
No. 48 40
Baseline, mean (SD) 88.9 (38.7) 77.3 (34.8)
Follow-up, mean (SD) 81.2 (34.8) 81.2 (42.5)
Difference (95% CI) −2.3 (−14.7 to 10.0) NA
P value .70 NA
Abbreviations: LDL, low-density lipoprotein; NA, not applicable.
SI conversion factors: To convert LDL cholesterol to millimoles per liter, multiply
by 0.0259; hemoglobin A1c to proportion of total hemoglobin, multiply by 0.01.
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adherence. Freedistribution also lowered systolic bloodpres-
sure and therewas a suggestion of better diabetes control, al-
though resultsdidnot reach statistical significance.Therewas
no effect on low-density lipoprotein cholesterol levels. There
was no increase in potentially inappropriate prescribing and
therewas no substantial difference in serious adverse events.
Participants receiving free medicine distribution were more
likely to report being able tomake endsmeet; the hypothesis
that medicine access allows people to afford other necessi-
ties can be tested in future studies.
To our knowledge, no previous trial has assessed the ef-
fect of providing a wide range of medicines for free, includ-
ing treatments for chronicnoncommunicabledisease (eg, dia-
betes and rheumatoidarthritis), chronic infectiousdisease (eg,
HIV and AIDS), and acute conditions (eg, pneumonia) and
symptoms (eg, pain). A trial of free access to secondary pre-
ventionmedicines after amyocardial infarction foundgreater
adherence in a higher risk population (38.9% in usual access
patients, comparedwith 26.6% in our study) andmodest im-
provements with free access (absolute increase, 5.4%).4 Off-
setting copayments for clopidogrel bisulfate or ticagrelor af-
ter anacutemyocardial infarction increasedadherenceslightly
(absolute increase, 3.3%) but didnot affectmajor adverse car-
diovascular events.23 Although improving medicine adher-
ence is difficult—only 5 of 17 complex interventions involving
frequentpatient contactmodestly improvedadherence3—even
relatively small increases in adherence to effective treat-
ments seem to improve health outcomes such as cardiovas-
cular events or reduce mortality such as HIV- and AIDS-
related mortality in higher risk individuals.4,7
Health improvements with free distribution are sup-
portedby thechanges in somesurrogatehealthoutcomes.The
mean systolic blood pressure reduction of 7.2 mm Hg ob-
served here is likely large enough to reducemortality at some
baseline levels.24 The observed small reduction in hemoglo-
bin A1c of 0.38%, if true, may be enough to reduce microvas-
cular complications, based on trials of intensive control.25 At
thesametime,manypatientsdidnot see improvements in sur-
rogate outcomes despite free distribution of medicines, em-
phasizing that cost is only one of several contributors to non-
adherence and that medicines are just one part of care.
The setting anddesignof the trial allows inferences about
the causal effects of essentialmedicine access to bedrawnbe-
causeall participantshadaccess topublicly fundedhealth care
services. The study population included people with a range
of incomelevelsandsourcesanddifferentethnicitieswho lived
in urban and rural settings.
Limitations
Findings fromonehigh-incomecountryshouldbeappliedwith
caution in jurisdictionswithdifferenthealth care services and
disease burdens. All the participants self-reported cost-
related nonadherence, and the effect of free medicine distri-
butionwill presumably be smaller where adherence is better.
At the same time, all participants had the option to apply for
public insurance (which would have capped drug payments
at approximately 4% of annual income) and others had pub-
lic or private insurance, so the free distribution may be ben-
eficial even in populations with some insurance. We did not
measureadherenceatbaselineandsocannotdetermine if free
distribution depends on the baseline level of adherence.
Unblindedallocation to freemedicinedistribution couldhave
motivated participants to exaggerate their adherence or re-
sulted in different care fromclinicians. The respective contri-
butions of the different aspects of thismultifaceted interven-
tion, including free access andmailing of prescriptions, were
not assessed in this 2-group trial, although mailing medi-
cines isassociatedwith improvedadherence.26There isno ideal
method for determining medicine adherence because pa-
tient reports can overestimate adherence and objective mea-
sures such as medical record reviews can underestimate it.
Wecouldnot confirmadherencewithelectronicpill bottle cap
devices in a subset of participants as planned because most
participantsdidnot returnthedevices.Thereweremissingdata
for the surrogate health outcomes as we did not provide cli-
nicians with any instructions about checking blood pressure
or laboratory indexesbecausedoingsomighthaveaffected the
outcomes. The cost-effectiveness of the intervention will be
assessedafter the24-month trial is complete; aprevious study
has estimated that purchasing thesemedicines in bulk for the
entire Canadian populationwould save approximately $4 bil-
lionperyear,withan incremental government cost of approxi-
mately $1 billion per year.27 This study was not designed or
powered to assess effects onmortality ormorbidity, although
the provided medicines include highly effective ones.
Conclusions
In this randomized clinical trial, distributing essential medi-
cines at no charge improved adherence to treatment with ef-
fective medicines. These results could help inform policy
changes such as publicly funding a list of essential medicines
as recommended by the Canadian Advisory Council on the
Implementation of National Pharmacare.28
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